Arming oncolytic herpes simplex virus with CXCL-11, IL-12 and a single-chain antibody against PD-1 to enhance CAR-T cell therapy in pancreatic ductal adenocarcinoma - PubMed
6 hours ago
- #pancreatic cancer
- #CAR-T cell therapy
- #oncolytic virus
- Engineered oncolytic herpes simplex virus oHSV30 expresses CXCL-11, IL-12, and a single-chain anti-PD-1 antibody to enhance CAR-T cell therapy for pancreatic ductal adenocarcinoma (PDAC).
- CAR-T cell therapy in PDAC faces challenges like immunosuppressive microenvironment, limited tumor infiltration, modest anti-tumor activity, and short-term T-cell persistence.
- Combination of CAR-T cells with intratumoral oHSV30 administration significantly reduced tumor burden and prolonged survival in immunocompetent and immunodeficient syngeneic PDAC mouse models.
- oHSV30 enhances CAR-T cell infiltration, cytotoxicity, and persistence in the tumor microenvironment, potentially serving as a promising adjuvant for CAR-T therapy in PDAC.